Antibacterial Agents TRIZ Cases

Controlled extrusion disrupts Arthrospira cells under specific pressure and temperature, increasing antimicrobial yield without killing the organisms.

Novel pyrimidine derivatives inhibit MLK3 and LRRK2 kinases to treat multiple diseases.

SlpA chaperone fusion partners prevent heat-induced aggregation of target proteins, ensuring stability up to 56°C.

Stable povidone-iodine and bromfenac ophthalmic composition formulation.

PDE4 modulators inhibit phosphodiesterase 4 to control immune responses, avoiding viral resistance and excessive inflammation.

Segmented antigen cassettes target acute infection, latency, and reactivation stages to overcome BCG limitations against latent tuberculosis.

Formula I diamides block N-acetylglucosaminidases, overcoming resistance from cell wall recycling.

Bacillus subtilis QST713 treats gastrointestinal disorders through pathogen competition and metabolite production.

Annexin V masks pathogen phosphatidylserine to block immunosuppressive signals, restoring immune detection of intracellular infections.

Gel permeation chromatography measures molecular size of saccharide conjugates, resolving quality control reliability issues in vaccine batch monitoring.

Administering a TLR4 antagonist mitigates corneal inflammation without steroid-induced ocular pressure risks.

Novel Pseudomonas strains produce RejuAgro A to suppress bacterial and oomycete infections without environmental pollution.

Meta-substituted azomethine compounds combat antibiotic-resistant infections with low MIC values.

Benzimidamide pentamidine analogs inhibit gram-negative bacterial growth while reducing toxic side effects.

Single agents regulating lipid, lipoprotein, insulin, and glucose levels address limitations of existing multi-drug therapies.

Substituted 1H-benzimidazole-4-carboxamides inhibit the PARP enzyme to treat cancer and inflammatory disorders.

Optimized CDR sequences achieve a dissociation constant below 9×10^-10 M, resolving sensitivity and specificity trade-offs in detection.

A recombinant protein vaccine uses distinct epitopes to induce a targeted immune response against cardiovascular disease antigens.

Small molecules inhibit and disrupt Salmonella biofilms, achieving 3-4.5 log bacterial burden reduction in the gallbladder.

Short fatty acid tail polymyxin derivatives reduce nephrotoxicity while maintaining antibacterial effectiveness against multiresistant Gram-negative bacteria.

A combined vaccine formulation merges live Lawsonia intracellularis antigens with PCV, Mycoplasma hyopneumoniae, and PRRSV components to elicit protective immunity.

Deuterated amlexanox extends drug lifetime by slowing metabolic derivatization, resolving rapid clearance issues in obesity and diabetes treatments.

A biaryl amide compound with specific stereochemistry acts as a potent CRTh2 modulator for respiratory treatment.

Alkyl esters of medium chain fatty acids inhibit pathogens while avoiding rapid absorption in the proximal small intestine.

Tamarind seed polysaccharide compositions stimulate host immune responses for topical antimicrobial treatment.

Pyrrolotriazinone compounds inhibit ubiquitin-specific protease 7 activity, addressing the lack of potent small molecule inhibitors for cancer treatment.

Segmented chimeric polypeptides with YxxL motifs amplify immunogenic exosome production without complex delivery systems.

Engineered exogenous DNA fragments with limited unprotected endonuclease sites inhibit bacterial growth, reducing antibiotic reliance and off-target effects.

Bacillus stearothermophillus and Bacillus subtilis microorganisms compete with pathogens on skin surfaces.

Phenyllactic acid inhibits antibiotic-resistant Helicobacter pylori infection without causing adverse reactions.

Quinoline derivatives inhibit the bacterial F1F0 ATP synthase enzyme, depleting cellular energy levels to treat resistant infections.

Water-soluble polymer conjugation extends the in vivo half-life of protegrin peptides, reducing rapid clearance and sustaining therapeutic activity.

A breakable vial integrates a sterile brush applicator within a hermetic seal for immediate topical use.

Structural optimization of polyphenylene ethynylene compounds enables selective bacterial membrane disruption while preserving mammalian cell integrity.

Modular synthesis of substituted tetrahydropyrimidine methanones overcomes multi-drug resistance in Mycobacterium tuberculosis.

Polygonus cuspidatum extracts act as photosensitizers to inactivate microorganisms via light irradiation.

Heating germanium dioxide with amino acids in water produces stable, alkali-free complexes for pharmaceutical use.

Modified glycolipid analogues boost antibody titers and resolve the trade-off between pharmacokinetic stability and immune response enhancement.

Bifunctional compounds recruit CDK9 to E3 ligases via a linker, triggering proteasomal degradation to overcome systemic concentration limits.

Antisense oligomers hybridize to bacterial mRNA to block translation, restoring antibiotic susceptibility against resistant pathogens.

Novel heterocyclic compounds overcome bacterial antibiotic resistance by inhibiting beta-lactamase activity and enhancing antibacterial efficacy.

Aromatic cationic peptides cross cell membranes via energy-independent diffusion to deliver molecular cargo directly into the cytoplasm.

Hydrolytic and oxidative enzymes degrade Pseudomonas aeruginosa biofilms, restoring antibiotic potency against recurrent otitis media.

Composite binding molecules evade protein A and Sbi binding while neutralizing leukotoxins, resolving proteolytic degradation issues in MRSA therapy.

Converting the hygroscopic free base to a crystalline mesylate salt improves thermal stability and reduces moisture absorption for pharmaceutical manufacturing.

Secretory IgA antibodies target the Campylobacter flagellar-capping protein FliD to limit bacterial motility and enhance immune clearance.